At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,377 enrolled
Drug / intervention
Beclomethasone Dipropionate/Formoterol Fumarate +1 moredrug
Likely dose
Beclomethasone Dipropionate/Formoterol Fumarate 6 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 Week, Randomized, Double-blind, Multicenter, Active Controlled, 2-Arm Parallel Group Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose (Fixed Combination of Extrafine Beclomethasone Dipropionate Plus Formoterol Fumarate) Compared to CHF 718 pMDI 800µg Total Daily Dose (Extrafine Beclomethasone Dipropionate) in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
In Brief
A Phase 3 clinical trial evaluating Beclomethasone Dipropionate/Formoterol Fumarate and Beclomethasone Dipropionate for Asthma. Completed, enrolled 1,377 participants across 91 sites.
Detailed Summary
Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartAug 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedMar 23, 2022
Enrollment StartAug 31, 2022
Primary CompletionJun 24, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.3 years ago
Interventions
Beclomethasone Dipropionate/Formoterol Fumaratedrug
Available in pressurized inhalation solution BDP/FF 200/6 µg
Beclomethasone Dipropionatedrug
Available in pressurized inhalation solution BDP 100 µg